Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR.

J Clin Oncol. 2004 Jun 1;22(11):2141-9.

PMID:
15169800
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

PMID:
16544313
[PubMed - indexed for MEDLINE]
Free Article
3.

Prostate brachytherapy: a descriptive analysis from CaPSURE.

Lee WR, Sharkey J, Cowan JE, DuChane J, Carroll PR; CaPSURE Investigators.

Brachytherapy. 2007 Apr-Jun;6(2):123-8.

PMID:
17434105
[PubMed - indexed for MEDLINE]
4.

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).

Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR.

J Urol. 2005 May;173(5):1557-61.

PMID:
15821485
[PubMed - indexed for MEDLINE]
5.

Contemporary trends in low risk prostate cancer: risk assessment and treatment.

Cooperberg MR, Broering JM, Kantoff PW, Carroll PR.

J Urol. 2007 Sep;178(3 Pt 2):S14-9. Epub 2007 Jul 20.

PMID:
17644125
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR.

J Urol. 2003 Nov;170(5):1804-7.

PMID:
14532780
[PubMed - indexed for MEDLINE]
7.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
[PubMed - indexed for MEDLINE]
8.

Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.

Park S, Meng MV, Elkin EP, Speight JL, DuChane J, Carroll PR.

J Urol. 2005 Nov;174(5):1802-7.

PMID:
16217291
[PubMed - indexed for MEDLINE]
9.

Time trends and local variation in primary treatment of localized prostate cancer.

Cooperberg MR, Broering JM, Carroll PR.

J Clin Oncol. 2010 Mar 1;28(7):1117-23. doi: 10.1200/JCO.2009.26.0133. Epub 2010 Feb 1.

PMID:
20124165
[PubMed - indexed for MEDLINE]
Free PMC Article
10.
11.

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.

Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H.

J Clin Oncol. 2009 Sep 10;27(26):4306-13. doi: 10.1200/JCO.2008.21.5228. Epub 2009 Aug 10.

PMID:
19667269
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR; CaPSURE Investigators.

J Urol. 2004 Apr;171(4):1393-401. Review.

PMID:
15017184
[PubMed - indexed for MEDLINE]
13.

Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.

Beyer DC, Thomas T, Hilbe J, Swenson V.

Brachytherapy. 2003;2(2):77-84.

PMID:
15062144
[PubMed - indexed for MEDLINE]
14.

Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.

Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y.

Jpn J Clin Oncol. 2010 Jun;40(6):588-92. doi: 10.1093/jjco/hyq008. Epub 2010 Mar 18.

PMID:
20299498
[PubMed - indexed for MEDLINE]
Free Article
15.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
[PubMed - indexed for MEDLINE]
16.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
[PubMed - indexed for MEDLINE]
17.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

PMID:
19509351
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

National practice patterns and time trends in androgen ablation for localized prostate cancer.

Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR.

J Natl Cancer Inst. 2003 Jul 2;95(13):981-9.

PMID:
12837834
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
[PubMed - indexed for MEDLINE]
20.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.

BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. Review.

PMID:
22239226
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk